Chief Medical Officer

Sheldon Sloan, MD, MBE, is Chief Medical Officer. With over 30 years of experience in the life sciences, healthcare, and medicine fields, Dr. Sloan is passionate about advancing science and improving the lives of patients. Dr. Sloan most recently served as Chief Medical Officer of Abivax, where he was responsible for leading medical strategy to support the lead Phase 3 program, develop lifecycle strategy for lead and follow on compounds, investor interface, business development support, and building a Phase 3 medical infrastructure including Clinical Development, Pharmacovigilance, Bioinformatics, Medical Affairs, and Clinical Pharmacology. Prior to Abivax, Dr. Sloan was Vice President and Program Lead for etrasimod UC at Pfizer, where he was responsible for leading the etrasimod UC cross functional team and overseeing NDA and MAA submission. Prior to Pfizer, Dr. Sloan was also Vice President and Program Lead for etrasimod GI at Arena Pharmaceuticals, Inc., a company that was acquired by Pfizer in March 2022, where he was responsible for leading the cross functional etrasimod UC team for the Phase 3 program. Earlier in his career, Dr. Sloan held different leadership positions at Johnson and Johnson in Medical Affairs, Research and Development, and Science Policy, including Global Medical Affairs Leader for IBD. He holds a Doctor of Medicine from Rush Medical College, Chicago, a Master of Bioethics from the University of Pennsylvania and a Bachelor of Science from University of Illinois Urbana-Champaign. Dr. Sloan currently serves on the Columbia University Masters of Bioethics Advisory Board, the Drexel University Dornsife School of Public Health Dean’s Impact, Advancement and Learning Council, and the American Gastroenterological Association Ethics Committee.